Merck KGaA (MRK.DE) stock: key figures, P/E, revenue and dividend
Health Care · Germany · ISIN DE0006599905
Merck KGaA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 21.16 bn EUR | 21.10 bn EUR |
| Gross profit | 11.95 bn EUR | 11.89 bn EUR |
| Operating income | 4.21 bn EUR | 3.93 bn EUR |
| EBIT | 4.37 bn EUR | 4.07 bn EUR |
| Net income | 2.78 bn EUR | 2.61 bn EUR |
| Diluted EPS – continuing operations | 6.39 EUR | 6.00 EUR |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
More stocks
- Shin-Etsu Chemical Co Ltd (4063.T)
- O'Reilly Automotive (ORLY)
- Republic Services (RSG)
- KDDI Corp (9433.T)
- Ferrari NV (RACE.MI)
- FedEx (FDX)
- Japan Post Bank Co Ltd (7182.T)
- Bloom Energy Corp (BE)
- Samsung Electro-Mechanics (009150.KS)
- American Electric Power (AEP)
- Vinci SA (DG.PA)
- Relx PLC (REL.L)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.